evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,922 questions · 3,118 findings · 513 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 574 · 18.4%GRADE not reported 372 · 11.9%Very low 723 · 23.2%Low 854 · 27.4%Moderate 489 · 15.7%High 106 · 3.4%

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Anuria · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Non‐fatal cardiovascular events · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Cough · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in cough compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Hyperkalaemia · patients receiving PD

Angiotensin receptor blockers (ARBs) showed no clear difference in hyperkalaemia compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Death (all causes) · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Doubling of SCr Median · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review